Tag Archives: biotechnology law

Federal Circuit Opinion On Myriad Remand

Posted on August 16, 2012 by Warren Woessner

Today, the Federal Circuit issued its opinion following GVR from the Supreme Court in AMP v. USPTO and Myriad Genetics, Inc., App. No. 2010-1406 (August 16,2012). (A copy of the opinion is available at the end of this post.) Unfortunately, … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , | 1 Comment

“Global Dossier” May Lead to IP5 “One Portal” Filings

Posted on August 3, 2012 by Warren Woessner

As reported in Director Kappos’ blog, progress is being made in harmonizing the patent filing process in the IP5 countries. This may be as big an advance in patent law as the EPO – including our hope for a single … Continue reading →

Posted in Int'l Practice and Policy | Tagged , , , , , , | Leave a comment

PTO Rules on Pre-issuance Submissions by Third Parties

Posted on July 20, 2012 by Warren Woessner

On July 17th, the USPTO released the rules that will govern the mandate in Section 8 of the AIA that requires the Office to provide for the submission by third parties of patents, published patent applications and other materials that … Continue reading →

Posted in Patent Reform Legislation, USPTO Practice and Policy | Tagged , , , , , , , | 1 Comment

“In Leukemia Treatment, Glimpses of the Future” of Medicine and IP

Posted on July 9, 2012 by Warren Woessner

A provocative article in the Sunday New York Times recounted how a young cancer researcher, who was diagnosed with acute lymphoblastic leukemia (ALL), and who responded but relapsed twice after receiving chemotherapy and bone marrow transplant, achieved a third remission … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | Leave a comment